• Skip to main content

Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

  • How To Publish
  • How to Write Plain Language Summaries
  • Frequently Asked Questions
  • Publications
    • Animated Videos
    • Bladder, Kidney and Genitals
    • Brain and Nerves
    • Cancer
    • Diabetes and Metabolic Hormones
    • Eyes and Vision
    • Heart and Circulation
    • Infections
    • Inflammatory and Immune-related disorders
    • Mental Health
    • Muscle and Bone
    • Rare Diseases
    • Skin
    • Vaccines
  • Advisory Panel
  • Supporters
  • Blog
  • About Us
  • Contact Us

Oct 18 2021

Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study

A new plain language summary in Future Oncology describes in detail the INVICTUS study originally published in the journal Lancet Oncology. The INVICTUS study looked at ripretinib as a potential treatment for advanced gastrointestinal stromal tumor.

Read the full article here.

The original article, called ‘Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial’ was published in Lancet Oncology and can be read here.

  • Share on Twitter Share on Twitter
  • Share on Facebook Share on Facebook
  • Share on LinkedIn Share on LinkedIn

Written by Joanne Walker · Categorized: Cancer · Tagged: gastrointestinal stromal tumor, Qinlock®, ripretinib, tyrosine kinase inhibitor

Copyright © 2023 · Plain Language Summaries · Terms and Conditions · Privacy Policy ·